Drug data last refreshed 18h ago · AI intelligence enriched 6d ago
CILOXAN is a ciprofloxacin hydrochloride ophthalmic solution approved in 1990 for bacterial eye infections and corneal ulcers. It is a fluoroquinolone antibiotic delivered as eye drops that works by inhibiting bacterial DNA gyrase. The product treats patients with acute bacterial conjunctivitis, corneal ulcers, and other ophthalmic infections.
As an older small-molecule product approaching loss of exclusivity with modest Part D spending ($1M), teams are likely focused on cost management and preparation for generic competition.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on CILOXAN offers limited growth opportunities given its mature lifecycle and approaching loss of exclusivity, making it better suited for professionals focused on portfolio defense, cost optimization, and managed decline. Careers on this product are most valuable for those seeking experience in legacy brand management and transition planning rather than innovation or launch activities.
Worked on CILOXAN at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo